Printable Handouts

PDF

Navigable Slide Index

1. Introduction (1)
2. Introduction (2)
3. Introduction (3)
4. Current and future reimbursement mechanisms
5. Price, reimbursement and health economics
6. Who is paying the bill
7. Reimbursement of new drugs - a pricing issue
8. The dynamic of price vs. reimbursement
9. Payers are exploring ways of reducing costs
10. Efficacy, safety and quality - no longer sufficient
11. Achieving market access was a "negotiation"
12. Increasing data and evidence is demanded
13. EU states have mechanisms to control budget
14. Measuring "value" is challenging
15. Pharmacoeconomics - attempting to quantify value
16. Quality adjusted life year (QALY)
17. A new drug value and its adoption can vary
18. Delays between authorisation and market access
19. The future for payers? (1)
20. The future for payers? (2)
21. Who will fund incremental improvement?
22. The future for pharmaceuticals?
23. Politics and ethics will drive future reimbursements
24. Who is paying in developed/developing countries
25. The future will be shaped by political decisions
26. The current political vision is not black and white
27. Introduction: Lee Blansett
28. Structures and philosophies differ
29. Fragmented health funding
30. Spending growth is cyclical
31. Part D raises federal Rx spend
32. U.S. expenditures twice EU levels
33. Many players in 4th hurdle
34. Private payers shift costs
35. Formularies enable negotiation
36. Fourth tiers shift high costs
37. Cost sharing drives prescribing
38. So, what's next in the U.S.?
39. Scattered signs of pressure
40. Generics ease pricing pressure
41. Risk of federal negotiations
42. A vague road to value
43. We'll know value when we see it?
44. Plans' prayers answered?
45. Biomarkers' use inconsistent
46. Value-based pricing clear?
47. Conclusions
48. Acknowledgements

Topics Covered

• Different structures and philosophies: EU and US
• Fragmented health funding
• US expenditure
• Private payers shift costs
• Cost sharing
• Generics
• Risk of federal negotiations
• Biomarkers
• Is value based pricing clear?
• Pricing, reimbursement and market access issues in Europe
• Current and future reimbursement mechanisms
• Why EU states intervene
• the dynamics of price versus reimbursement
• Effective way of reducing the cost of healthcare
• Launching new products
• EU countries and mechanisms of controlling their budget
• Pharmaeconomics
• Cost utility analysis and quality adjusted life year
• Politics, ethics and future reimbursement systems

Links

Series:

• Pharmaceutical Marketing (2009)

Categories:

• Marketing & Sales
• Strategy

Talk Citation

Publication History

• Published on January 28, 2009